LNA Antisense Oligonucleotide Targeting miR-128 for DMD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are limited in efficacy, with existing therapies only modestly improving symptoms for a small percentage of patients and associated with significant side effects, highlighting the need for novel therapeutic approaches.
Innovation Solution
Administration of an inhibitory nucleic acid targeting miR-128, specifically a locked nucleic acid (LNA) antisense oligonucleotide, to modulate the expression of proteins involved in mitochondrial metabolism, thereby addressing the underlying pathologies of DMD and BMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (steroids, exon-skipping therapy) are administered to DMD patients, then some symptom improvement is achieved, but the efficacy is limited and only benefits a small percentage of patients
Solution Approach 1:
The invention extracts and targets the specific pathological mechanism involving miR-128 upregulation in dystrophic muscle, separating this novel therapeutic approach from conventional treatments that address different aspects of the disease. By focusing on miR-128 inhibition, the therapy addresses a specific molecular pathway that is dysregulated in DMD, potentially benefiting patients who do not respond to exon-skipping therapy
Solution Approach 2:
The invention changes the therapeutic parameter from protein-level intervention (steroids, exon-skipping) to nucleic acid-level intervention (antisense oligonucleotides targeting miR-128). This parameter change enables a different mechanism of action that can restore expression of dystrophin-regulated genes, potentially expanding treatment options to patients who do not qualify for or respond to existing therapies
2Reliability
If current DMD treatments are administered, then modest symptom improvement is achieved, but significant side effects occur
Solution Approach 1:
The invention uses antisense oligonucleotides as intermediary molecules that specifically bind to and inhibit miR-128, a key mediator in the pathological pathway. This intermediary approach allows for targeted inhibition of the harmful miR-128 effect without the systemic side effects associated with steroid therapy, as the oligonucleotide acts locally at the molecular level to restore gene expression
Solution Approach 2:
The invention converts the harmful effect of miR-128 upregulation (which suppresses dystrophin-regulated genes and contributes to muscle pathology) into a therapeutic opportunity by designing oligonucleotides that specifically inhibit miR-128. By targeting the root molecular cause rather than managing symptoms, the treatment addresses the underlying pathology without the side effects of conventional symptom-management approaches
3Use of energy by moving object
If miR-128 is inhibited using antisense oligonucleotides, then mitochondrial metabolism and energy expenditure are improved, but the complexity of the therapeutic mechanism increases
Solution Approach 1:
The invention performs preliminary action by inhibiting miR-128 before it can suppress the expression of critical mitochondrial and metabolic genes (PGC-1α, SIRT1, AMPKα2, CPT1β, PPARα). By blocking miR-128 early in the regulatory pathway, the treatment allows these genes to be expressed at normal levels, thereby restoring mitochondrial biogenesis and energy metabolism without requiring direct manipulation of each individual gene
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment significantly improves muscle function, increases mitochondrial numbers, and enhances energy expenditure in skeletal muscle, leading to reduced muscle weakness and improved muscle mass, with potential benefits in delaying or preventing dilated cardiomyopathy.
Implementation Method 1
administering an inhibitory nucleic acid that targets miR-128
Data Source
AI summary
Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.